Efficacy of monoclonal anti-tumour necrosis factor-α antibodies in uveitic macular oedema
OBJECTIVES: To assess the efficacy of anti-tumour necrosis factor (TNF)-α agents in the treatment of refractory uveitic macular oedema (UME).
METHODS: Patients with refractory UME treated with TNF-α blockers were retrospectively enrolled. Central macular thickness (CMT) was assessed at optical coherence tomography (OCT) at the start of TNF-α inhibition, after 3 and 12 months, and at the last follow-up visit.
RESULTS: Thirty-six patients (56 eyes with UME) were enrolled. The mean follow-up period was 29.9±40.8 (4-184) months. A statistically significant decrease was observed in the frequency of UME (p<0.0001) and in the mean CMT values (p<0.0001) during the study period. Best corrected visual acuity improved in 35 eyes (62.5%), remained stable in 12 eyes (21.4%), reduced in 9 eyes (16.1%). The mean corticosteroid dosage significantly decreased during the study period (p=0.016).
CONCLUSIONS: TNF-α inhibitors represent a useful treatment in patients with severe or resistant UME.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:38 |
|---|---|
| Enthalten in: |
Clinical and experimental rheumatology - 38(2020), 4 vom: 14. Juli, Seite 621-625 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tosi, Gian Marco [VerfasserIn] |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 17.09.2020 Date Revised 17.09.2020 published: Print-Electronic Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM302987584 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM302987584 | ||
| 003 | DE-627 | ||
| 005 | 20231225111859.0 | ||
| 007 | tu | ||
| 008 | 231225s2020 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n1009.xml |
| 035 | |a (DE-627)NLM302987584 | ||
| 035 | |a (NLM)31694738 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tosi, Gian Marco |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Efficacy of monoclonal anti-tumour necrosis factor-α antibodies in uveitic macular oedema |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 17.09.2020 | ||
| 500 | |a Date Revised 17.09.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a OBJECTIVES: To assess the efficacy of anti-tumour necrosis factor (TNF)-α agents in the treatment of refractory uveitic macular oedema (UME) | ||
| 520 | |a METHODS: Patients with refractory UME treated with TNF-α blockers were retrospectively enrolled. Central macular thickness (CMT) was assessed at optical coherence tomography (OCT) at the start of TNF-α inhibition, after 3 and 12 months, and at the last follow-up visit | ||
| 520 | |a RESULTS: Thirty-six patients (56 eyes with UME) were enrolled. The mean follow-up period was 29.9±40.8 (4-184) months. A statistically significant decrease was observed in the frequency of UME (p<0.0001) and in the mean CMT values (p<0.0001) during the study period. Best corrected visual acuity improved in 35 eyes (62.5%), remained stable in 12 eyes (21.4%), reduced in 9 eyes (16.1%). The mean corticosteroid dosage significantly decreased during the study period (p=0.016) | ||
| 520 | |a CONCLUSIONS: TNF-α inhibitors represent a useful treatment in patients with severe or resistant UME | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Tumor Necrosis Factor-alpha |2 NLM | |
| 700 | 1 | |a Vitale, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Rigante, Donato |e verfasserin |4 aut | |
| 700 | 1 | |a Sota, Jurgen |e verfasserin |4 aut | |
| 700 | 1 | |a Emmi, Giacomo |e verfasserin |4 aut | |
| 700 | 1 | |a Lopalco, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Guerriero, Silvana |e verfasserin |4 aut | |
| 700 | 1 | |a Iannone, Florenzo |e verfasserin |4 aut | |
| 700 | 1 | |a Vannozzi, Lorenzo |e verfasserin |4 aut | |
| 700 | 1 | |a Bitossi, Alice |e verfasserin |4 aut | |
| 700 | 1 | |a Frediani, Bruno |e verfasserin |4 aut | |
| 700 | 1 | |a Cantarini, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Fabiani, Claudia |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical and experimental rheumatology |d 1989 |g 38(2020), 4 vom: 14. Juli, Seite 621-625 |w (DE-627)NLM012613010 |x 0392-856X |7 nnns |
| 773 | 1 | 8 | |g volume:38 |g year:2020 |g number:4 |g day:14 |g month:07 |g pages:621-625 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 38 |j 2020 |e 4 |b 14 |c 07 |h 621-625 | ||